

Technology Advisory Committee D Interests Register
Efgartigimod for treating generalised myasthenia gravis [ID4003]
Publication Date: 7 February 2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Rachel Elliot	Committee Member	Direct – financial	Rachel received payment by CSL Behring for an advisory board this year on an unrelated topic	03/07/2023	It was agreed that Rachel's declaration would not prevent her from participating in discussions on this appraisal
Ivan Koychev	Committee Member	Direct- Non-financial personal interest	Ivan declared that a close friend of his is Senior Medical Director at Argenx.	16/11/2023 18/07/2023	It was agreed that Ivan's declaration would not prevent him from participating in discussions on this appraisal
Dr Channa Hewamadduma	Clinical Expert	Direct – financial	Dr Hewamadduma declared the following financial interests: <ul style="list-style-type: none"> UCB Pharma Received funding for consultancy on scientific or educational advisory boards 	16/11/2023 26/06/2023	It was agreed that Dr Hewamadduma's declarations would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul style="list-style-type: none"> • Argenx Received funding for consultancy on scientific or educational advisory boards • Lupin Received funding for consultancy on scientific or educational advisory boards • Roche Received funding for consultancy on scientific or educational advisory boards • Biogen Received funding for consultancy on scientific or educational advisory boards • Association of British Neurologists (ABN)- Chaired a symposium organised by Biogen on SMA- new insights from basic science to understand SMA • Association of British Neurologists (ABN) –Lecture on Mechanisms of Myasthenia gravis – in an educational symposium on MG arranged by ARGENX • One off Consultation for UCB 		

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Channa Hewamadduma	Clinical Expert	Direct-non financial Indirect - professional	<p>Dr Hewamadduma declared his involvement in clinical trials in MG/CIDP: sponsors: UCB, Argenx (ongoing), Jansen (setup)</p> <p>Dr Hewamadduma also declared the following indirect interests:</p> <ul style="list-style-type: none"> • Publication- author – Contributing author to Phase 3 clinical trial and manuscript. Lancet Neurology 2023 (May) • 2023 March: Core teaching faculty of an Academic programme on Myasthenia Gravis at Neurology Academy- who were sponsored by ARGENX and UCB 	26/06/2023	It was agreed that Dr Hewamadduma's declarations would not prevent him from providing expert advice to the committee.
Dr Fiona Norwood	Clinical Expert	Direct – financial and non-financial interests	<p>Dr Norwood declared the following interests:</p> <ul style="list-style-type: none"> • Speaking engagement for argenx • Advisory board for argenx • Advisory board for UCB • Trustee for patient organisation Myaware 	16/11/2023 12/12/2022	It was agreed that Dr Norwood's declarations would not prevent her from providing expert advice to the committee.